No.

Compound name

Prognosis of pharmacological effects Pa/Pi type of activity

Prognosis of toxic effects Pa/Pi type of toxicity

3

N-(β-D-xylopyranozyl)- thiosemicarbazide

6 of 464 Possible Pharmacological Effects at Pa > 0.500

0.654 0.007 Antimycobacterial

0.637 0.037 Antineoplastic

0.593 0.005 Antidiabetic symptomatic

0.576 0.004 Antineoplastic (small cell lung cancer)

0.548 0.005 Restenosis treatment

0.523 0.010 Antituberculosic

9 of 321 Possible Toxic and Adverse Effects at Pa > 0.500

0.747 0.010 Hyperuricemia

0.680 0.046 Neuritis

0.664 0.052 Renal insufficiency

0.643 0.031 Acidosis, metabolic

0.628 0.042 Acidosis

0.640 0.067 Anemia, hemolytic

0.640 0.067 Hyperactivity

0.574 0.111 Dysesthesia

0.512 0.089 Optic neuritis

4

N-(β-D-galactopiranozyl)- thiosemicarbazide

14 of 464 Possible Pharmacological Effects at Pa > 0.500

0.799 0.004 Antimycobacterial

0.718 0.004 Antituberculosic

0.700 0.004 Restenosis treatment

0.679 0.007 Antiviral (Influenza)

0.685 0.029 Antineoplastic

0.628 0.013 Antiviral (Pox-virus)

0.586 0.005 Antidiabetic symptomatic

0.543 0.005 Antiviral

0.564 0.028 Immunostimulant

0.549 0.014 DNA synthesis inhibitor

0.539 0.005 Antioxidant

0.544 0.013 Antibacterial

0.511 0.024 Cytostatic 0.508 0.022 Antidiabetic

23 of 321 Possible Toxic and Adverse Effects at Pa > 0.500

0.818 0.005 Hyperuricemia

0.689 0.039 Diarrhea

0.682 0.047 Renal insufficiency

0.682 0.049 Myocardial ischemia

0.652 0.048 Hypoxia

0.628 0.035 Optic neuritis

0.620 0.042 Psychoses

0.605 0.027 Peripheral neuropathy

0.599 0.046 Optic neuropathy

0.596 0.080 Hyperactivity

0.549 0.051 Ototoxicity